Physician profile
Chad E Bonhomme
NPI 1760432470
$924,659.88
in general payments reported to CMS, 2019-2025
19 companies · $8,968 in 2025
The $8,968 reported for 2025 was more than what 78% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,505 · 2020: $3,079 · 2021: $121K · 2022: $721K · 2023: $59K · 2024: $2,259 · 2025: $8,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,750 · Food and Beverage: $3,189 · Travel and Lodging: $9.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $60,390.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,750.00 |
| Food and Beverage | $3,188.59 |
| Travel and Lodging | $9.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $897,309.60 | 2019-2025 | Acticor 7 Vr-T Dx, Rivacor 7 Dr-T, Edora 8 Dr-T |
| Kilele Health INC | $6,750.00 | 2025 | |
| Boston Scientific Corporation | $5,632.35 | 2019-2025 | Rhythmia Mapping System, Farapulse |
| Abbott Laboratories | $5,600.65 | 2019-2025 | Aveir, Gallant, Allure |
| Pfizer INC. | $5,194.93 | 2019-2025 | |
| Medtronic Vascular, INC. | $1,197.07 | 2019-2020 | |
| Biosense Webster, INC. | $1,076.31 | 2021-2025 | Carto 3 |
| Medtronic, INC. | $975.74 | 2021-2024 | Na |
| Cardiofocus, INC. | $394.70 | 2019-2024 | Heartlight System |
| Cardiva Medical, INC. | $163.84 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Globus Medical, INC. | $85.71 | 2025 | Vyrsa V1 |
| Philips North America LLC | $64.54 | 2021 | |
| Acarix USA INC. | $53.55 | 2025 | Cadscor System |
| Janssen Pharmaceuticals, INC | $52.25 | 2019-2020 | |
| Novo Nordisk INC | $36.92 | 2025 | Ozempic, Rybelsus |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $23.86 | 2022 | |
| Astellas Pharma US INC | $17.98 | 2019 | |
| Seqirus USA INC | $16.89 | 2025 | Flucelvax, Fluad |
| Cardinal Health 200 LLC | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$904.89 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Bonhomme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.